Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Stoke Therapeutics, Inc. (STOK : NSDQ)

• Company Description    Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford, Massachusetts. Number of Employees: 102

• Price / Volume Information    Yesterday's Closing Price: $14.13 Daily Weekly Monthly 20 Day Moving Average: 320,214 shares Shares Outstanding: 39.14 (millions) Market Capitalization: $553.10 (millions) Beta: 0.65 52 Week High: $41.60 52 Week Low: $12.59 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.66% -9.84% 12 Week -27.94% -19.02% Year To Date -41.10% -28.04%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 45 WIGGINS AVENUE - BEDFORD,MA 01730 USA ph: 781-430-8200 fax: - ir@stoketherapeutics.com http://www.stoketherapeutics.com

• General Corporate Information    Officers Edward M. Kaye - Chief Executive Officer Stephen J. Tulipano - Chief Financial Officer Julie A. Smith - Director Seth L. Harrison - Director Adrian R. Krainer - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 86150R107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 39.14 Most Recent Split Date: (:1) Beta: 0.65 Market Capitalization: $553.10 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.70 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.86 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 7.55% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.30 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -43.48% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -39.42 12/31/21 - -34.92 09/30/21 - -28.89 ROA 03/31/22 - -34.92 12/31/21 - -33.13 09/30/21 - -27.73 Current Ratio 03/31/22 - 13.35 12/31/21 - 13.37 09/30/21 - 20.61 Quick Ratio 03/31/22 - 13.35 12/31/21 - 13.37 09/30/21 - 20.61 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -3,122.03 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 6.13 12/31/21 - 5.92 09/30/21 - 6.46 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©